n the paper by Marmagkiolis et al. (1) 
plasminogen activator (t-PA), history of diabetes and atrial fibrillation, 90-day modified Rankin Scale Regarding safety, a major concern is that patients may be at risk of ICH after endovascular recanalization therapy. We may deduce that higher rates of recanalization after ET come at the expense of a higher rate of hemorrhage; however, this was not observed in any of the RCTs. The rates of symptomatic ICH in the endovascular groups ranged from 0% to 7.7% and were not different from those for the IV t-PA-alone group.
Mortality was similar in both groups across studies.
In all these studies, patients achieved significantly increased rates of recanalization and functional outcomes, without increasing the risk of symptomatic ICH or death. We previously reported that decreased cerebral blood volume in the basal ganglia may be associated with the risk of hemorrhagic conversion after recanalization and reperfusion (7). 
